Trial ID or NCT#

NCT02654483

Status

not recruiting iconNOT RECRUITING

Purpose

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

Official Title

A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients

Eligibility Criteria

Ages Eligible for Study: Older than 13 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jean Y. Tang MD PhD
Jean Y. Tang MD PhD
General dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Professor of Dermatology at the Stanford University Medical Center
Albert Sean Chiou, MD, MBA
Albert Sean Chiou, MD, MBA
Dermatologist
Clinical Assistant Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

Claudia Teng
725-7152